cp-55,940 has been researched along with Adjuvant Arthritis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Shamma, H; Behan, DP; Chen, C; Chen, R; Choi, K; Dang, H; Decaire, M; Edwards, J; Fu, L; Gaidarov, I; Gatlin, J; Han, S; Jones, RM; Jung, JK; Morgan, M; Narayanan, S; Pride, C; Sadeque, A; Semple, G; Solomon, M; Strah-Pleynet, S; Thatte, J; Thoresen, L; Unett, DJ; Usmani, KA; Whelan, K; Xiong, Y; Yue, D; Zhu, X | 1 |
1 other study(ies) available for cp-55,940 and Adjuvant Arthritis
| Article | Year |
|---|---|
Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.
Topics: Administration, Oral; Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Heterocyclic Compounds, 3-Ring; Humans; Inflammation; Male; Microsomes, Liver; Models, Molecular; Molecular Structure; Osteoarthritis; Pain; Pyrazoles; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Stereoisomerism; Structure-Activity Relationship | 2015 |